New drug targets tough esophageal cancer in early trial
NCT ID NCT07405151
First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 6 times
Summary
This study tests a drug called I-DXd in 60 people with advanced esophageal cancer that has worsened after prior treatments. I-DXd is designed to attach to cancer cells and deliver a toxic payload to destroy them. The main goal is to see how many patients' tumors shrink or disappear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ifinatamab deruxtecan (I-DXd)
- What this could lead to
- If it works, this could offer a new treatment option for advanced esophageal cancer that has stopped responding to other therapies.
- What could go wrong
- This is an early-phase trial with only 60 participants, so results may not apply broadly. The drug may cause side effects or fail to shrink tumors in many patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Aichi Cancer Center ( Site 2702)
RECRUITINGNagoya, Aichi-ken, 464-8681, Japan
-
Asan Medical Center ( Site 2901)
RECRUITINGSeoul, 05505, South Korea
-
Beijing Cancer Hospital ( Site 2500)
RECRUITINGBeijing, Beijing Municipality, 100142, China
-
Chang Gung Memorial Hospital - Linkou Branch ( Site 3006)
RECRUITINGTaoyuan, 33305, Taiwan
-
Chang Gung Memorial Hospital at Kaohsiung ( Site 3003)
RECRUITINGKaohsiung City, 83301, Taiwan
-
China Medical University Hospital ( Site 3007)
RECRUITINGTaichung, 40447, Taiwan
-
Faculty of Medicine Siriraj Hospital ( Site 3102)
RECRUITINGBangkoknoi, Bangkok, 10700, Thailand
-
Hopitaux Universitaires de Geneve HUG ( Site 3701)
RECRUITINGGeneva, 1211, Switzerland
-
Jinan Central Hospital ( Site 2507)
RECRUITINGJinan, Shandong, 250000, China
-
Kanagawa Cancer Center ( Site 2701)
RECRUITINGYokohama, Kanagawa, 241-8515, Japan
-
Kantonsspital Graubünden-Medizin ( Site 3700)
RECRUITINGChur, Kanton Graubünden, 7000, Switzerland
-
Liga Norte Riograndense Contra o Cancer ( Site 3301)
RECRUITINGNatal, Rio Grande do Norte, 59062-000, Brazil
-
Masarykuv onkologicky ustav ( Site 4000)
RECRUITINGBrno, Brno-mesto, 565 53, Czechia
-
National Cancer Center ( Site 2902)
RECRUITINGGoyang-si, Kyonggi-do, 10408, South Korea
-
National Cancer Center Hospital ( Site 2700)
RECRUITINGChūō, Tokyo, 104-0045, Japan
-
National Cheng Kung University Hospital ( Site 3001)
RECRUITINGTainan, 704, Taiwan
-
National Taiwan University Cancer Center (NTUCC) ( Site 3010)
RECRUITINGTaipei, 106, Taiwan
-
National Taiwan University Hospital ( Site 3000)
RECRUITINGTaipei, 10002, Taiwan
-
Oslo universitetssykehus, Radiumhospitalet ( Site 3501)
RECRUITINGOslo, 0379, Norway
-
Samsung Medical Center ( Site 2900)
RECRUITINGSeoul, 06351, South Korea
-
Songklanagarind Hospital ( Site 3101)
RECRUITINGHat Yai, Changwat Songkhla, 90110, Thailand
-
Taipei Veterans General Hospital ( Site 3005)
RECRUITINGTaipei, 11217, Taiwan
-
UPMC Hillman Cancer Center ( Site 3904)
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.